The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell …
YH Huang, KH Hsu, JS Tseng, TY Yang, KC Chen… - Targeted Oncology, 2022 - Springer
Background Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the
standard first-line treatment for patients with advanced and recurrent EGFR-positive non …
standard first-line treatment for patients with advanced and recurrent EGFR-positive non …
[HTML][HTML] A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset …
K Ito, M Morise, K Wakuda, O Hataji, T Shimokawaji… - ESMO open, 2021 - Elsevier
Background FLAURA, the prospective trial of osimertinib as a first-line therapy compared
with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) …
with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) …
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: a single-group, open-label …
H Hayashi, K Yonesaka, A Nakamura, D Fujimoto… - Lung Cancer, 2022 - Elsevier
Introduction Alternation of osimertinib and afatinib is a potential approach to overcome
osimertinib resistance and to allow complementation of drug efficacy without compromising …
osimertinib resistance and to allow complementation of drug efficacy without compromising …
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2020 - Future Medicine
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR
mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and …
mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and …
Clinical outcomes of afatinib versus osimertinib in patients with non-small cell lung cancer with uncommon EGFR mutations: a pooled analysis
C Wang, K Zhao, S Hu, W Dong, Y Gong, C Xie - The Oncologist, 2023 - academic.oup.com
Background The purpose of this analysis was to investigate the effectiveness of afatinib
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …
[HTML][HTML] Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
S Gilardone, R Thapa, J Laborde… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background The optimal treatment sequencing for patients with metastatic epidermal growth
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of …
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of …
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
S Gen, I Tanaka, M Morise, J Koyama, Y Kodama… - BMC cancer, 2022 - Springer
Background Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients …
tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients …
[HTML][HTML] Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
T Araki, S Kanda, M Komatsu, K Sonehara… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and …
revolutionized the treatment of advanced non-small cell lung cancer (NSCLC) and …
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CH Chen, JWC Chang, CF Chang… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Afatinib is a standard treatment for patients with advanced non–small cell
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
[HTML][HTML] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced …
D Zhang, X Liu, F Shen, D Zhao, Y Shi… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background In the phase 3 FLAURA trial, osimertinib was compared with first-generation
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line …